Vapaliximab is a chimeric monoclonal antibody[1] and an experimental immunosuppressive drug.[citation needed] Development was discontinued by 2012.[2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric (mouse/human) |
| Target | VAP-1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
References
edit- ^ WHO Drug Information
- ^ "Vapaliximab - AdisInsight". adisinsight.springer.com. Retrieved 2 January 2019.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |
 | This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it. |